0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Reductase Inhibitors and the Risk of Cancer

Mark R. Goldstein, MD
Arch Intern Med. 2001;161(11):1460. doi:.
Text Size: A A A
Published online

Extract

The nested case-control study by Dr Blais et al1 provided some reassurance regarding the safety of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. However, important issues remain unresolved.

In their cohort of older beneficiaries of a health care plan, those treated with HMG-CoA reductase inhibitors were less likely to be diagnosed as having cancer than those treated with bile acid sequestrants. Because the median period of follow-up for the cohort was only 2.7 years, this study does not offer long-term reassurance. Neoplasia from carcinogens can take decades to clinically manifest.2 This is not as important in older individuals at high risk for coronary events because neoplasia from the drug might not clinically manifest in their lifetime, whereas protection from coronary events should occur rapidly.3 However, in younger individuals HMG-CoA reductase inhibitors are potentially administered for decades, and there is a possibility for neoplasia from the drug to manifest during their lifetime.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
[Alcohol drinking as a risk factor for cancer]. Fukuoka Igaku Zasshi 2014;105(5):111-6.
Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol 2014;810():33-51.
Jobs
brightcove.createExperiences();